Genmab A/S GNMSF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GNMSF is a good fit for your portfolio.
News
-
AbbVie Gets New FDA Accelerated Approval for Epkinly
-
Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug
-
Pfizer, Genmab get full FDA approval for cervical-cancer drug
-
Correction to Genmab Article
-
Genmab Strengthens Oncology Portfolio With $1.8 Billion Acquisition of ProfoundBio
-
AbbVie, Genmab Get Speedy FDA Review of Epkinly in Follicular Lymphoma
-
Genmab, Pfizer Get European Review of Cervical Cancer Drug
-
Pfizer, Genmab Get Speedy FDA Review of Tivdak Full Approval
Trading Information
- Previous Close Price
- $279.82
- Day Range
- $272.41–287.64
- 52-Week Range
- $241.09–421.26
- Bid/Ask
- $243.08 / $321.37
- Market Cap
- $17.29 Bil
- Volume/Avg
- 1,195 / 674
Key Statistics
- Price/Earnings (Normalized)
- 22.02
- Price/Sales
- 6.94
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.46%
Company Profile
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 2,266
- Website
- https://www.genmab.com
Competitors
Valuation
|
Metric
|
GNMSF
|
4502
|
INCY
|
|---|---|---|---|
Price/Earnings (Normalized) | 22.02 | 16.11 | 18.09 |
Price/Book Value | 3.77 | 0.92 | 2.86 |
Price/Sales | 6.94 | 1.57 | 4.12 |
Price/Cash Flow | 18.37 | 7.69 | 19.81 |
Price/Earnings
GNMSF
4502
INCY
Financial Strength
|
Metric
|
GNMSF
|
4502
|
INCY
|
|---|---|---|---|
Quick Ratio | 12.42 | 0.51 | 3.29 |
Current Ratio | 12.46 | 1.11 | 3.47 |
Interest Coverage | 216.18 | 1.35 | 333.13 |
Quick Ratio
GNMSF
4502
INCY
Profitability
|
Metric
|
GNMSF
|
4502
|
INCY
|
|---|---|---|---|
Return on Assets (Normalized) | 15.15% | 5.19% | 13.25% |
Return on Equity (Normalized) | 16.99% | 11.01% | 17.32% |
Return on Invested Capital (Normalized) | 14.01% | 7.28% | 14.51% |
Return on Assets
GNMSF
4502
INCY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Kjknzqkv | Mcpn | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fbxgjfcl | Hwrxdx | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hfqrgqmmd | Hzxkwn | $118.7 Bil | |||
| Moderna Inc
MRNA
| Xmrhqbkjv | Ycfb | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kmtfwcn | Vkznqfb | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Xyvnkcs | Nys | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Gqwnqrq | Nzkb | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mgnyltkz | Twggqf | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Vgyzvjq | Zmw | $15.0 Bil | |||
| Incyte Corp
INCY
| Xjgwdppzz | Mhzvkkb | $13.5 Bil |